Company Overview and News

0
Santa Fe Gold Records $5.17 Million Gross for 2017 and Net Income of $2.38 Million through June 30, 2017

2018-07-05 globenewswire
ALBUQUERQUE, N.M., July 05, 2018 (GLOBE NEWSWIRE) -- Santa Fe Gold Corporation (OTC:SFEG), a U.S. based mining and exploration enterprise with emphasis on Gold, Silver, Copper, Precious, Industrial and Base metals and owner of multiple claims, including eight advanced projects containing numerous additional mine sites with near term production potential is pleased to announce a net profit of $2,384,542 on other income of $5,172,597.
SFEGQ SVL SFEG

0
Silver Mines extends high-grade zone at the Bowdens Silver project

2018-06-22 proactiveinvestors.com.au
Silver Mines Ltd’s(ASX:SVL) drilling has extended the high-grade northwest mineralised zone at its Bowdens Silver project near Mudgee in New South Wales.
SVL

0
Santa Fe Gold Encounters Exceptional Silver Grades of up to 36 Oz Per Ton From Alhambra Tailings Pre-Production Tests

2018-05-22 globenewswire
Thirteen Additional Surface Mine Vein and Tailings Assays Are Ongoing As Part Of Santa Fe's Advanced One Hundred Plus Sample Program With More Comprehensive In Depth Cross Sectional Silver Vein And Random Mine Trench Test Results Soon
SFEGQ SVL SFEG

0
Silver Mines raises $2.75 million for world-class silver deposit

2018-04-04 proactiveinvestors.com.au
Silver Mines Ltd (ASX:SVL) has raised $2.75 million in a share placement to sophisticated and professional investors priced at 4 cents.
SVL

0
Santa Fe Gold Records $4.18 Million Net Income Over Six Months Thru March 2017

2018-03-28 globenewswire
Company Reports Net Income of $3,281,049 for Fiscal Q3 March 2017 Adding to $902,666 in December 2016 Quarter For Total Net Income Of $4,183,715 Over Previous 6 Months
SFEGQ SVL SFEG

0
Santa Fe Gold To Immediately Commence Pre-Production Tests At Its $839 Million Alhambra Silver Mine

2018-03-16 globenewswire
Santa Fe Gold's newly acquired Black Hawk/Bullard's Peak district is known to contain over 100 different veins, 27 of which show silver mineralization at the surface as mapped and described in previous United States Geologic Surveys. The property includes four historic producing mines: The Black Hawk, Alhambra, Good Hope and the Silver King mines.
SFEGQ SVL SFEG

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Silicon Investor Message Boards

This table lists all message boards related to ASX:SVL / SILVER MINES LIMITED on message board site Silicon Investor.

Silver Crest Mines Inc. : SVL.V